Eli Lilly Covid-19 Antibody Treatment Granted Emergency FDA Authorization

2 min read
fairly difficult
"This emergency authorization allows us to make bamlanivimab available as a COVID-19 treatment for recently diagnosed, high-risk patients—adding a valuable tool for doctors fighting the now-increasing burden of this global pandemic," Eli Lilly CEO David Ricks said.

A coronavirus antibody treatment from pharmaceutical company Eli Lilly received an emergency use authorization from the Food and Drug Administration Monday, a significant step for recently diagnosed patients at risk of progressing to a more severe case of the virus.

David Ricks, chairman and CEO of Eli Lilly and Company, speaks at an event on protecting seniors ... [+] with diabetes in the Rose Garden White House, Tuesday, May 26, 2020, in Washington. AP Photo/Evan Vucci

Key Facts

The drug, called bamlanivimab, is meant to be given to patients by health care providers right after they test positive and within 10 days of symptom onset to prevent further progression and hospitalization. The FDA notably warns against its use for patients who are already hospitalized, as an NIH-sponsored trial was halted last month after scientists concluded it was unlikely to help at that point. Data from an ongoing clinical trial for patients with…
Rachel Sandler
Read full article